SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has sponsored a supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM) focusing on classic congenital adrenal hyperplasia (CAH), ...

Crinetics Pharmaceuticals announced positive topline results from a Phase 2 study of atumelnant, a novel oral ACTH receptor antagonist, for treating congenital adrenal hyperplasia (CAH).

capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal ...

Additionally, rapid, substantial and sustained statistically significant reductions in 17-OHP, a confirmatory secondary biomarker of disease control, were achieved across doses. Treatment with ...

Victorian newborns will soon be tested for a potentially deadly genetic disorder as the state expands its heel prick testing ...

Adrenal insufficiency diagnosis was more accurate and reliable with baseline cortisol alongside DHEAS measurements.

Jefferies has upgraded Crinetics (CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company's drug atumelnant. Read more here.

(Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant, a novel, once-daily oral ...

The U.S. Food and Drug Administration (FDA) has granted approval to crinecerfont, an innovative oral drug designed to treat classic congenital adrenal hyperplasia (CAH) in patients aged four years ...

Pharmaceuticals announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia, CAH, study of ...

Crinetics Pharma reports positive results from phase 2 trial of atumelnant in congenital adrenal hyperplasia: San Diego Monday, January 13, 2025, 16:30 Hrs [IST] Crinetics Pharmac ...